A very recent preclinical study in fact showed that regression of HER2-positive breast cancer PDX models with the potent H1047 PIK3CA mutations could only be achieved with the addition of everolimus to neratinib, but not with neratinib alone25,26. This evidence concerns the gene ERBB2 and breast cancer.